Assetmark Inc. Buys 82,275 Shares of Jazz Pharmaceuticals PLC $JAZZ

Assetmark Inc. lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9,759.8% during the 2nd quarter, HoldingsChannel reports. The firm owned 83,118 shares of the specialty pharmaceutical company’s stock after acquiring an additional 82,275 shares during the period. Assetmark Inc.’s holdings in Jazz Pharmaceuticals were worth $8,820,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hurley Capital LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $25,000. Picton Mahoney Asset Management grew its holdings in shares of Jazz Pharmaceuticals by 2,445.5% during the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of Jazz Pharmaceuticals during the 1st quarter valued at approximately $36,000. Hantz Financial Services Inc. grew its holdings in shares of Jazz Pharmaceuticals by 471.4% during the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 297 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Up 1.0%

NASDAQ:JAZZ opened at $137.64 on Friday. The firm’s fifty day moving average is $132.19 and its 200-day moving average is $118.24. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The firm has a market cap of $8.35 billion, a P/E ratio of -20.45, a P/E/G ratio of 8.49 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same period in the prior year, the company posted $5.30 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director directly owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last 90 days, insiders have sold 11,500 shares of company stock valued at $1,525,280. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on JAZZ shares. Morgan Stanley set a $183.00 price target on shares of Jazz Pharmaceuticals in a report on Friday, October 24th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a report on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $179.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.